| abstract |
Hydroxyimino-fluorene derivative compound of the formula (1) wherein R5 and R6 are each independently hydrogen, halo, or a C1-8 alkyl, C1-8 alkoxy, aryl, heteroaryl, acyl, thioalkyl, sulfonyl, or substituted sulfoxyl or not substituted; and X is CY or N, where Y is hydrogen, halo, NH2, NO2, or an alkyl, cycloalkyl, heterocycloalkyl, alkoxy, alkenyl, aryl, heteroaryl, aryloxy, alkylamino, dialkylamino, thioalkyl, acyl, sulfonyl, sulfoxide or thioaryl , substituted or unsubstituted; or a pharmaceutically accepted prodrug of said compound, a pharmaceutically active metabolite of said compound, or a pharmaceutically accepted salt of said compound or metabolite. These compounds and the pharmaceutical compositions that contain them, are capable of mediating the transduction of the tyrosine kinase signal to modulate and / or inhibit the proliferation of undesirable cells. The use of such compounds in the manufacture of medicaments for the treatment of cancer and other diseases associated with angiogenesis and / or undesirable cell proliferation, such as diabetic retinopathy, neovascular glaucoma, rheumatoid arthritis and psoriasis, is also described. |